Expert Interview
Exploring Sanofi's BTK inhibitor Rilzabrutinib for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP)
Ticker(s): SNYInstitution: University of Vermont
- Clincal Associate Professor of Medicine at the University of Vermont School of Medicine
- Manages 15-20 patients a month with Immune Thrombocytopenia
- Clinical interest in Immune Thrombocytopenia and Bone marrow transplantation
Describe your background and practice setting
Added By: ben_adminWhat is the current standard of care for treating chronic ITP?
Added By: ben_adminWhat are your initial thoughts on the data from the Phase 3 LUNA trial?
Added By: ben_adminPlease describe your clinical practice; roughly how many patients with immune thrombocytopenia (ITP) do you currently manage?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
